Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis
online resource
posted on 2021-10-17, 20:43 authored by Hannah A. BlairDeclarations
Funding The preparation of this review was not supported by any external funding.
Authorship and Conflict of interest Hannah Blair is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.
Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability Not applicable.
Additional information about this Adis Drug
Review can be found here.
Abstract
Subcutaneous secukinumab
(Cosentyx®) is a recombinant, fully human, immunoglobulin (Ig)
G1κ monoclonal antibody targeted against interleukin (IL)-17A, a
proinflammatory cytokine involved in the pathogenesis of psoriasis. Secukinumab
is approved in the EU and the USA for the treatment of
moderate to severe plaque psoriasis in pediatric patients aged ≥ 6 years. In pivotal phase III
trials in pediatric patients aged 6 to < 18 years, both low
(75–150 mg) and high (75–300 mg) doses of secukinumab were significantly
better than placebo and numerically better than etanercept at week 12 in
terms of the proportion of patients achieving ≥ 75% improvement from baseline
in Psoriasis Area and Severity Index and significantly better than placebo and
etanercept in terms of the proportion of patients achieving an Investigator’s
Global Assessment score of 0 or 1. The clinical efficacy of secukinumab observed
during the first 12 weeks of treatment was maintained over the longer term.
Treatment with secukinumab improved health-related quality of life and was
generally well tolerated. In conclusion, secukinumab represents a valuable
new addition to the limited treatment options
available for children and adolescents with moderate to severe plaque
psoriasis.
© Springer Nature Switzerland AG 2021
